Ignite Creation Date:
2025-12-24 @ 3:40 PM
Ignite Modification Date:
2025-12-29 @ 3:26 PM
Study NCT ID:
NCT01255592
Status:
COMPLETED
Last Update Posted:
2015-10-08
First Post:
2010-12-02
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis
Sponsor:
AstraZeneca
Organization:
Study Overview
Official Title:
A Phase II Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28-Day Oral Administration of AZD5069 Twice Daily in Patients With Bronchiectasis
Status:
COMPLETED
Status Verified Date:
2015-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
STRATUS
Brief Summary:
The purpose of this study is to investigate the effect of AZD5069 in patients with bronchiectasis.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: